Reviews Depo-Estradiol


No reviews yet.

Depo-Estradiol Drug Description
DEPO®-ESTRADIOL
(estradiol cypionate) Injection, USP

WARNINGS:
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures including endometrial sampling, when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of “natural” estrogens results in a different endometrial risk profile
than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS,
malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen-alone
therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION
DEPO-Estradiol Injection contains estradiol cypionate for intramuscular use.
Each mL contains:
5 mg/mL—5 mg estradiol cypionate, 5.4 mg chlorobutanol anhydrous (chloral derivative)
added as preservative; in 913 mg cottonseed oil.
Warning: Chlorobutanol may be habit forming. The structural formula
is represented below:








DEPO-Estradiol contains an oil soluble ester of estradiol 17β. The chemical name for estradiol cypionate is estradiol 17-cyclopentanepropionate.
Last reviewed on RxList: 8/25/2009




Depo-Estradiol Drug Description
DEPO®-ESTRADIOL
(estradiol cypionate) Injection, USP

WARNINGS:
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures including endometrial sampling, when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of “natural” estrogens results in a different endometrial risk profile
than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS,
malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen-alone
therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION
DEPO-Estradiol Injection contains estradiol cypionate for intramuscular use.
Each mL contains:
5 mg/mL—5 mg estradiol cypionate, 5.4 mg chlorobutanol anhydrous (chloral derivative)
added as preservative; in 913 mg cottonseed oil.
Warning: Chlorobutanol may be habit forming. The structural formula
is represented below:








DEPO-Estradiol contains an oil soluble ester of estradiol 17β. The chemical name for estradiol cypionate is estradiol 17-cyclopentanepropionate.
Last reviewed on RxList: 8/25/2009




Depo-Estradiol Drug Description
DEPO®-ESTRADIOL
(estradiol cypionate) Injection, USP

WARNINGS:
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures including endometrial sampling, when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of “natural” estrogens results in a different endometrial risk profile
than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS,
malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen-alone
therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION
DEPO-Estradiol Injection contains estradiol cypionate for intramuscular use.
Each mL contains:
5 mg/mL—5 mg estradiol cypionate, 5.4 mg chlorobutanol anhydrous (chloral derivative)
added as preservative; in 913 mg cottonseed oil.
Warning: Chlorobutanol may be habit forming. The structural formula
is represented below:








DEPO-Estradiol contains an oil soluble ester of estradiol 17β. The chemical name for estradiol cypionate is estradiol 17-cyclopentanepropionate.
Last reviewed on RxList: 8/25/2009




Depo-Estradiol Drug Description
DEPO®-ESTRADIOL
(estradiol cypionate) Injection, USP

WARNINGS:
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures including endometrial sampling, when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of “natural” estrogens results in a different endometrial risk profile
than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS,
malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen-alone
therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION
DEPO-Estradiol Injection contains estradiol cypionate for intramuscular use.
Each mL contains:
5 mg/mL—5 mg estradiol cypionate, 5.4 mg chlorobutanol anhydrous (chloral derivative)
added as preservative; in 913 mg cottonseed oil.
Warning: Chlorobutanol may be habit forming. The structural formula
is represented below:








DEPO-Estradiol contains an oil soluble ester of estradiol 17β. The chemical name for estradiol cypionate is estradiol 17-cyclopentanepropionate.
Last reviewed on RxList: 8/25/2009




Depo-Estradiol Drug Description
DEPO®-ESTRADIOL
(estradiol cypionate) Injection, USP

WARNINGS:
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures including endometrial sampling, when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of “natural” estrogens results in a different endometrial risk profile
than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS,
malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen-alone
therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION
DEPO-Estradiol Injection contains estradiol cypionate for intramuscular use.
Each mL contains:
5 mg/mL—5 mg estradiol cypionate, 5.4 mg chlorobutanol anhydrous (chloral derivative)
added as preservative; in 913 mg cottonseed oil.
Warning: Chlorobutanol may be habit forming. The structural formula
is represented below:








DEPO-Estradiol contains an oil soluble ester of estradiol 17β. The chemical name for estradiol cypionate is estradiol 17-cyclopentanepropionate.
Last reviewed on RxList: 8/25/2009





Other reviews about Depo-Estradiol on wordpress

What's new... And Old... And other than usual shit....
  by geekbrat
Well, Kim's FINALLY out of the hospital again... She came home this time the day before thanksgiving and is doing MUCH better thanshe was the first time she […]


ESTRING® (estradiol) Vaginal Ring
  by kanlayanee
[caption id="" align="alignnone" width="288" caption="ESTRING 2 MG VAGINAL RING PHARMACIA/UPJHN Approx. Price: $167.24 per 1Each"][/caption] Adult Min/Max Dose: 7.5mcgAll insert 1 vaginal ring by […]


Americans Need Help Getting Meds- How to Get Free or Reduced Needed RX medications
  by paganmedia
Thanks to USA federal government incentives, pharmaceutical companies may provide free prescription medicines if : Sourced and Submitted: By Lady Paradise ~ With much appreciated thanks on this […]


Ilkley, Yorkshire, Saturday [Novembe
  by jigvpufrils
Thats where my car got the best mileage. Martin History of the Dog 1845 page 203. And theres one thing I clean forgot. I wrinkled my brow, […]


I didnt know you were as English
  by mlvwmngriopyme
22:3 And it came to pass in the eighteenth year of king Josiah, that the king sent Shaphan the son of Azaliah, the son of Meshullam, the scribe, […]


I didnt know you were as English
  by mlvwmngriopyme
22:3 And it came to pass in the eighteenth year of king Josiah, that the king sent Shaphan the son of Azaliah, the son of Meshullam, the scribe, […]


Tonight, as at all times, th
  by hqmlcylznrh
Mike began to drink soup directly from the thermos in small sips. The vivid colour in her face had paled. Saying this, he stepped to the door, […]


The tree thrives well, beyond a dou
  by zfodthprhcetc
While we shall never weary in the defense of freedom, neither shall we ever abandon the pursuit of peace. Sometimes it was big and panicky, trampling everything: the […]


He went downstairs with h
  by jfhnpsshvrtmo
He adjusted his cards carefully, appraised their value and said, as he put out a token. Something that felt alive pressed briefly against her palm, and then was […]


She stood for a few moments helpl
  by mbasohmdoimil
Tegetmeier, by crossing a blackbreasted red Game cock with a white Game hen, and the pile subbreed thus produced can afterwards be truly propagated. You ought to obtain […]



Other reviews about Depo-Estradiol on web:

All about Depo-Estradiol. View complete and up to date Depo-Estradiol information - part of the Drugs.com trusted medication database. Depo-Estradiol Facts and Comparisons at Drugs.com


Physician reviewed Depo-Estradiol patient information - includes Depo-Estradiol description, dosage and directions. Depo-Estradiol medical facts from Drugs.com


Learn about the prescription medication Depo-Estradiol (Estradiol Cypionate Injection), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Depo-Estradiol (Estradiol Cypionate Injection) Drug Information ...


DEPO ®-ESTRADIOL Estradiol cypionate injection, USP WARNINGS: ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. DEPO®-ESTRADIOL Estradiol cypionate injection, USP


Depo-Estradiol is a prescription drug used to treat menopausal symptoms and hormone deficiencies. This eMedTV Web page provides a complete overview of Depo-Estradiol, including ... Depo-Estradiol


Consumer information about the medication ESTRADIOL CYPIONATE INJECTION (Dep-Gynogen, Depo-Estradiol, Depogen), includes side effects, drug interactions, recommended dosages ... ESTRADIOL CYPIONATE INJECTION (Dep-Gynogen, Depo-Estradiol ...


Information on the Pfizer product DEPO-ESTRADIOL. ... DEPO-ESTRADIOL ® (estradiol cypionate injection, USP) This product information is intended only for residents of the United States. DEPO-ESTRADIOL | Pfizer: the world's largest research-based ...


Depo-Estradiol side effects, dosage, and drug interactions. All accurate, up-to-date information is written for the consumer by healthcare professionals. Depo-Estradiol IM Uses and How to Use


Depo-Estradiol is an estrogen hormone used to treat certain symptoms of menopause or to prevent osteoporosis (weakened bones/bone loss). Side effects and interactions are available ... Depo-Estradiol - drugstore.com. Low prices, side effects ...


Learn about Depo-Estradiol IM - its uses, dosage, side effects, drug interactions, and safety information on RxList. Depo-Estradiol IM Drug information on Uses, Side Effects ...





Featured Reviews

Reviews Enoxacin

Penetrex Drug Description DRUG DESCRIPTION What are the possible side effects of enoxacin (Penetrex)? If you experience any of the following serious side effects, stop taking enoxacin and seek emergency medical attention or contact...
Read More  |  Review This
Reviews Ciprofloxacin Extended-Release

Cipro XR Drug Description CIPRO® XR (ciprofloxacin*) Extended-Release Tablets WARNING Fluoroquinolones, including CIPRO® XR, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is...
Read More  |  Review This
Reviews Bicalutamide

Casodex Drug Description CASODEX® (bicalutamide) Tablet for Oral use DRUG DESCRIPTION What are the possible side effects of bicalutamide (Casodex)? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Reviews Tikosyn

Tikosyn Drug Description TIKOSYN ® (dofetilide) Capsules To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations...
Read More  |  Review This
Reviews Dipentum

Dipentum Drug Description DIPENTUM® (olsalazine sodium) Capsules DRUG DESCRIPTION What are the possible side effects of olsalazine (Dipentum)? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....